Results 11 to 20 of about 1,428 (167)

Tofogliflozin ameliorates cardiotoxin induced skeletal muscle injury and fibrosis in obesity [PDF]

Scientific Reports
Obesity impairs muscle function through effects on lipid metabolism, systemic inflammation, and insulin resistance, leading to muscle loss and reduced regeneration.
Muhammad Bilal, Nguyen Quynh Phuong, Tomonobu Kado, Jianhui Liu, Le Duc Anh, Sana Khalid, Muhammad Rahil Aslam, Memoona, Ayumi Nishimura, Yoshiko Igarashi, Yoshiyuki Watanabe, Waseem Abbas, Maki Yokoyama, Yasuhiro Onogi, Kenichi Hirabayashi, Seiji Yamamoto, Kunimasa Yagi, Marsel Lino, Isao Usui, Masaru Kato, Shiho Fujisaka, Allah Nawaz, Kazuyuki Tobe   +22 more
doaj   +5 more sources

Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice [PDF]

BMC Gastroenterology
Background Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes ...
Yoshinori Ozono, Hiroshi Kawakami, Hiroshi Hatada, Naomi Uchiyama, Souichiro Ogawa, Keisuke Uchida, Hotaka Tamura, Yuri Komaki, Kenichi Nakamura, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata   +11 more
doaj   +7 more sources

The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease [PDF]

Gastroenterology Insights, 2022
The increasing number of patients with fatty liver disease is a major health problem. Fatty liver disease with metabolic dysfunction has been recognized as nonalcoholic fatty liver disease (NAFLD).
Takeshi Goya, Koji Imoto, Shigeki Tashiro, Tomomi Aoyagi, Motoi Takahashi, Miho Kurokawa, Hideo Suzuki, Masatake Tanaka, Masaki Kato, Motoyuki Kohjima, Yoshihiro Ogawa   +10 more
doaj   +3 more sources

Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats [PDF]

Cells
Background: Liver cirrhosis leads to portal hypertension (PH) with capillarization of liver sinusoidal endothelial cells (LSECs), although drug treatment options for PH are currently limited.
Shohei Asada, Kosuke Kaji, Norihisa Nishimura, Aritoshi Koizumi, Takuya Matsuda, Misako Tanaka, Nobuyuki Yorioka, Shinya Sato, Koh Kitagawa, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji   +11 more
doaj   +4 more sources

Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI [PDF]

Journal of Diabetes Investigation
Aims/Introduction Patients with type 2 diabetes are at high risk of developing steatotic liver disease (SLD). Weight loss has proven effective in treating metabolic dysfunction‐associated steatotic liver disease (MASLD) in obese patients with type 2 ...
Hiroyuki Uchinuma, Mitsunori Matsushita, Masaya Tanahashi, Hideki Suganami, Kazunori Utsunomiya, Kohei Kaku, Kyoichiro Tsuchiya   +6 more
doaj   +4 more sources

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

BMJ Open Diabetes Research & Care, 2021
Introduction The treatment of diabetes has a significant impact on the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We compared the effectiveness of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and pioglitazone for ...
Atsushi Nakajima, Takeharu Yamanaka, Yasushi Honda, Kento Imajo, Masataka Taguri, Masato Yoneda, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Asako Nogami, Hiroyuki Kirikoshi, Tomoyuki Iwasaki, Takeo Kurihashi, Satoru Saito   +14 more
doaj   +2 more sources

Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats

BMJ Open Diabetes Research & Care, 2021
Introduction Sodium glucose cotransporter-2 (SGLT2) inhibitors are widely used for diabetes treatment. Although SGLT2 inhibitors have been clinically observed to increase food intake, roles or even the presence of SGLT2 in the central nervous system (CNS)
Kenji Takeda, Hiraku Ono, Ko Ishikawa, Tomohiro Ohno, Jin Kumagai, Hidetoshi Ochiai, Ai Matumoto, Hidetaka Yokoh, Koutaro Yokote   +8 more
doaj   +2 more sources

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus [PDF]

Journal of Diabetes Research, 2018
Sodium-glucose cotransporter 2 inhibitor tofogliflozin is a new type of antidiabetic drug for individuals with type 2 diabetes mellitus (T2DM). The aim of this study was to examine in which type of individuals and/or under which conditions tofogliflozin ...
Shinji Kamei, Masahiro Iwamoto, Miyuki Kameyama, Masashi Shimoda, Tomoe Kinoshita, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Fuminori Tatsumi, Kenji Kohara, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto   +13 more
doaj   +2 more sources

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

Cardiovascular Diabetology, 2023
Background This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an apparent history of
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Akira Kurozumi, Masahiro Hatazaki, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Ken Kato, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA study investigators   +26 more
doaj   +2 more sources

Development of a Scalable Synthesis of Tofogliflozin

The Journal of Organic Chemistry, 2016
An efficient and scalable synthesis of an antidiabetic drug, tofogliflozin (1), which was identified as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is described. A key factor in the synthesis of 1 was the selection of the purpose-designed protecting group, which plays a strategic role in protection, chemoselective activation ...
Yoshihito, Ohtake, Takashi, Emura, Masahiro, Nishimoto, Koji, Takano, Keisuke, Yamamoto, Satoshi, Tsuchiya, Sang-Yong, Yeu, Yasushi, Kito, Nobuaki, Kimura, Sunao, Takeda, Masao, Tsukazaki, Masatoshi, Murakata, Tsutomu, Sato   +12 more
openaire   +3 more sources